Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, has announced that Cyrus K. Mirsaidi is taking the worldwide helm as the Chief Executive Officer (CEO), including its pharmaceutical supplier division, LumaCina, and its Contract Development and Manufacturing Organisation (CDMO) division, NovaCina.

Mirsaidi has an accomplished leadership track record. As CEO of BioDuro-Sundia, he led the company growth from: 500 employees to 2,000+ employees and from 3 sites to 10 global sites, including multiple tuck-in acquisitions and a major merger. Mirsaidi continued as Board Advisor at BioDuro-Sundia, following his role as President and CEO.

Prior, he was President and CEO at Molecular Response, a translational oncology CRO, also funded by Bridgewest Group, where he successfully expanded and exited that business in 2015.  He has served as Chairman and Managing Partner at BioSelective Capital Investments, as Advisor to private equity firm, Advent International and Board Member at Sanguine Biosciences.

Mirsaidi also holds current appointments within Bridgewest Investment Group, that include the Investment Committee at Bridgewest Ventures New Zealand, and member of the Board of Directors at BioOra, LLC.

In April, Bridgewest Group had announced the acquisition of the Pfizer Perth cGMP sterile injectable manufacturing plant, and the formation of Bridgewest Perth Pharma, including the NovaCina CDMO division and LumaCina pharmaceutical supply division.  Over the past 6 months, the company has invested millions of dollars into both divisions, including broadening NovaCina manufacturing capability with a new isolator filling line, and expanding the LumaCina product catalogue and commercial markets.